Novo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy

Novo Nordisk reported a 26% increase in sales, driven largely by its GLP-1 drugs Ozempic and Wegovy, totaling $9.5 billion in revenue and surpassing estimates. However, Wegovy sales fell short of Wall Street expectations by 11%, despite increased prescriptions and a price reduction. The company also faces challenges from government investigations and patent concerns, particularly in the U.S. and Denmark, affecting its market strategy and pricing dynamics.